SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq:CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.